ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.64
0.22%
US Tech 100
20,266.40
0.33%
S&P 500
5,969.34
0.35%
US Dollar vs CAD
1.39805
0.00%
Bitcoin
96,828.99
-0.98%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) News

ARGX

Argen X (ARGX)

Argen X SE
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ARGX
DateTimeSourceHeadlineSymbolCompany
11/20/202412:00AMGlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesEU:ARGXArgen X SE
11/11/20246:30AMGlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaEU:ARGXArgen X SE
11/05/202412:00AMGlobeNewswire Inc.argenx to Participate at Upcoming Investor ConferencesEU:ARGXArgen X SE
10/31/20241:00AMGlobeNewswire Inc.argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
10/24/202412:00AMGlobeNewswire Inc.argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024EU:ARGXArgen X SE
10/15/202412:00AMGlobeNewswire Inc.argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsEU:ARGXArgen X SE
09/19/202412:00AMGlobeNewswire Inc.argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
08/28/202412:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
07/25/202412:00AMGlobeNewswire Inc.argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
07/18/202412:00AMGlobeNewswire Inc.argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024EU:ARGXArgen X SE
07/15/202411:30PMGlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaEU:ARGXArgen X SE
06/25/20243:30PMGlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingEU:ARGXArgen X SE
06/21/20243:50PMGlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
06/17/202412:00AMGlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024EU:ARGXArgen X SE
06/04/202412:00AMGlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceEU:ARGXArgen X SE
05/09/202412:00AMGlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
05/07/20244:30PMGlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersEU:ARGXArgen X SE
05/07/202412:00AMGlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceEU:ARGXArgen X SE
05/02/202412:00AMGlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
04/16/202412:00AMGlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
03/27/20241:00AMGlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
03/26/20243:00PMGlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
03/26/20241:00AMGlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
03/07/20243:01PMGlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
02/29/202412:00AMGlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
02/26/202412:00AMGlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
02/22/202412:00AMGlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
02/20/202412:00AMGlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
01/18/202412:00AMGlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
01/08/202412:00AMGlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX

Your Recent History

COIN
XRPUSD
Ripple
NASDAQ
COOP
Mr Cooper
NASDAQ
AVXL
Anavex Life Sciences
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
BIEL
Bioelectronics (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
FNMA
Fannie Mae (QB)
USOTC
AZRH
Azure (PK)
USOTC
RDGL
Vivos (QB)
USOTC
HIRU
Hiru (PK)
USOTC
RNVA
Rennova Health (CE)
USOTC
SPZI
Spooz (PK)
USOTC
RDAR
Raadr (PK)
USOTC
NBRI
North Bay Resources (PK)
NASDAQ
AMRN
Amarin
USOTC
CGAC
Code Green Apparel (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved